Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Horizon Discovery combines long scientific heritage in translational research with GENESIS™, a precision gene editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organisations.
Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. The largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development. IDT products support a wide variety of applications.
Synthego is the genome engineering innovation company. The company’s automated, full stack genome engineering platform enables broader access to CRISPR to accelerate basic scientific discovery, uncover cures for diseases and develop novel synthetic biology applications. Headquartered in Silicon Valley, Synthego is used by scientists from the largest global biotechnology companies and global biology universities to unlock the potential of gene editing.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevronproduced plasmids, RNA and gene editing enzymes for programs ranging from research to clinical trials to commercial applications. Aldevron’s Cas9 nuclease is available as an off-the-shelf product at research grade, GMP-Source and GMP quality levels, eliminating months typically associated with contract production. Additional gene editing enzymes will be available in the near future. Aldevron also custom manufactures enzymes, including Cas9 and other nucleases, to meet the most stringent specifications. Company headquarters are in Fargo, ND, with additional facilities in Madison, WI, and Freiburg, Germany. For more information, or to get in touch with our client support team, visit.
Cellecta provides highthroughput loss-offunction genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA, CRISPR, and barcode libraries; pooled library screening and analysis by NGS; targeted RNA-Seq for biomarker discovery; lentiviral reagents; and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.
Agilent Technologies is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, and expertise enabling customers to gain the insights they seek. Our solutions provide precise answers for disease and cancer research, drug discovery, and basic research. Agilent enables new discoveries by providing faster and innovative technologies to further research in the life sciences market.
Bio-ITech facilitates laboratories to improve efficiency and quality of research by providing comprehensive and flexible lab information management software. From offices in the US (Boston) and Europe (The Netherlands), we serve customers worldwide.
Based on the patented FluidFM technology, Cytosurge AG provides the unique FluidFM BOT system that optimizes CRISPR-Cas transfection by delivering CRISPR-Cas9 complexes directly to where they are required: the nucleus. This is made possible by the FluidFM nanosyringe, which is with its 500 nm aperture probably the world’s smallest syringe. It is ideal for nano-injecting into difficult to transfect cells such as hiPS, neurones and even recently cardiomyocytes.
In addition to nano-injection, the cutting-edge FluidFM BOT system can also perform other unique applications such as single cell isolation and nano-printing.
Seeing is believing – We look forward to meeting you at our booth and discussing how we could help you to optimize your CRISPR experiments.
Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and singleuse bioreactor vessels complement the range of highest-quality premium products. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics, and at industrial laboratories performing process analysis, production, and quality assurance.
Solentim® has established itself over the past 7 years as the world leader and innovator of new instruments for streamlining the cell line development workflow. We will feature the VIPS™ platform for high throughput, automated Single Cell Cloning which is a key step in any gene editing and cell engineering workflow. This system has many advantages over a FACS-based approach and additionally provides image documentation of clonality. To find out more information and watch the VIPS video visit production, and quality assurance.
For over 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. With more than 2300 patents and 90% of the world’s sequencing data run on our systems, we are just beginning to discover the true impact of genomics in areas we touch, including oncology, reproductive health, genetic disease, agriculture, and microbiology. This realization, and the discoveries we know lie ahead, inspire us to push boundaries and drive innovation.